key: cord-0944385-h1h10lvt
authors: Cheng, DR.; Wen, JQ.; Liu, ZZ.; Lv, TF.; Chen, JS.
title: Coronavirus disease 2019 in renal transplant recipients: report of two cases
date: 2020-05-16
journal: Transpl Infect Dis
DOI: 10.1111/tid.13329
sha: bc02cde75cda89cc7f0321b4f0c702ffbccf4674
doc_id: 944385
cord_uid: h1h10lvt

Coronavirus disease 2019 (COVID‐19) has been a pandemic worldwide. The data about COVID‐19 in renal transplant recipient is deficiency. Herein we report two COVID‐19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low‐dose methylprednisolone‐based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID‐19 in renal transplant recipients.

However the data about COVID-19 in renal transplant recipients is deficiency.

Renal transplant recipients are immunocompromised due to the use of immunosuppressant. Herein we report the clinical feature and management of two COVID-19 cases in renal transplant recipients.

Case1: A 48-year old male was admitted on February 10 with the chief complaint of intermittent fever for 13 days with a peak temperature of 37.5 ℃ , accompany by chest tightness asthenia without coughing. On February 6 a nasopharyngeal swabs specimen was obtained and sent for detection of SARS-CoV-2 nucleic acid; this was reported back within 24 hours as positive. At the same day a pulmonary computed tomography (CT) scan showed pulmonary inflammation. Local protocol for

This article is protected by copyright. All rights reserved COVID-19 was activated, the patient was diagnosed with COVID-19 and isolated immediately.

This patient received a renal transplantation in 2009 and was taking oral immunosuppressants consisting of tacrolimus, mycophenolate mofetil and prednisone with stable allograft function. From February 6 he had discontinued the immunosuppressant use, taking his doctor's advice.

The physical examination on admission revealed a body peak temperature of The patient had a peak fever of T39℃ on admission with dyspnea. Low-dose methylprednisolone (40mg qd) was given with symptomatic supportive treatment.

The patient's symptoms were improved gradually. SARS-CoV-2 nucleic acid test was negative for consecutive 3 times, CT scan on February 28 showed that bilateral lung lesions were absorbed more obviously than before (Figure1). The patient took the resumption of mycophenolate mofetil tacrolimus and discharged on March 3.

This article is protected by copyright. All rights reserved Case2: A 65-years old female was admitted on February 8 with the chief complaint of intermittent fever for 9 days with a peak temperature of 39℃, accompany by cough expectoration and chest distress muscle ache weakness for 4 days. A SARS-CoV-2 nucleic acids test was performed and confirmed positive 5 days prior to hospitalization. She was diagnosed with COVID-19 and isolated immediately with the administration of Arbibol and moxifloxacin, but it was not effective.

She received renal transplantation on 2011 and was taking oral immunosuppressants consisting of tacrolimus, prednisone and mycophenolate mofetil after surgery. The allograft function was stable. She stopped the immunosuppressants and only reserved prednisone in the guidance of the doctor on the second day onset of illness.

Physical evaluation showed that body temperature was 37.3℃, respiratory rate was 22 breaths per minute, oxygen saturation was only 83% in ambient air and could reach above 93% with oxygen therapy supplied at 3-5L/min. Laboratory results on hospital days 2 revealed a normal leukocyte count(4.7 × 10 9 /L), a reduced lymphocyte count(0.72×10^9/L), a low percentage of lymphocytes(15.3%), a normal thrombocyte and hemoglobin. The level of CRP elevated significantly (40.14 mg/L). Serum creatinine was 0.63mg/dl and Cystatin C was 1.05mg/L. the level of plasma albumin slightly decreased (32.9g/L) with negative proteinuria.

The patient was given high-flow nasal oxygen therapy (HFNT) at 40 L/min immediately after admission. The second day in hospital the patient's condition was deteriorating accompanied by chest tightness more obvious after exercise.

Non-invasive ventilator (NIV) was administered at 50% oxygen concentration and oxygen flow 40 L/min. Low-dose methylprednisolone (40mg qd), and human immunoglobulin for intravenous injection (IVIG) (5g qd) were given with symptomatic supportive treatment. The symptoms of the patient were alleviated gradually. NIV was switched to HFNT and at last to nasal cannula oxygen therapy 

COVID-19 RT-PCR(-), pulmonary CT: pneumonia cured

WHO Declares COVID-19 a Pandemic

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Coronaviruses and immunosuppressed patients. The facts during the third epidemic